(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM
Rated 4 out of 5 Vedazzling Wonderful experience I feel very protected when I wear them
Frequently Asked Questions About Epitalon What is Epitalon used for
The prior authorization systems, formulary management platforms, and electronic health record integrations that sit between a clinicians prescribing decision and a patient filling a prescription were not designed for a drug class of this complexity, this volume, or this clinical significance
En su lugar, utilizan extractos botnicos naturales y nutrientes que apoyan metabolismos saludables, ayudando en la gestin del apetito, promoviendo una utilizacin eficiente de los nutrientes y ayudando a mantener niveles de azcar en sangre ya dentro del rango normal